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ARTICLE  INFO ABSTRACT
Background: Metformin shows anti-proliferative effect on tumor cells. We 
studied the effect of metformin on achieving complete pathological response (pCR) 
in breast cancer patients receiving neoadjuvant therapy in a Latin American 
population. 
Methods: We conducted a cross-sectional study in Mexico Hospital, Costa Rica, 
from January 2007 to December 2015. Women with early-stage or locally advanced 
breast cancer receiving neoadjuvant systemic treatment were recruited for the study. 
Univariate and multivariate models were used to compare the pCR rate with 
metformin plus standard therapy versus standard treatment alone. 
Results: Of 53 included women with early-stage or locally advanced breast 
cancer were included, 14 received metformin with systemic therapy, and 39 had 
systemic therapy alone. Only 15% of the patients had diabetes mellitus. The pCR rate 
was in the metformin group was 64.3% compared with 23.1% in the systemic 
therapy-alone group (OR: 6.0, 95% CI: 1.60–22.53, P= 0.008). This finding was 
confirmed after adjustment for potential confounders, suggesting that the use of 
metformin increased the pCR likelihood regardless of breast cancer subtype (adjusted 
OR: 5.56, 95% CI: 1.27–24.3, P = 0.02). There was a trend of achieving pCR in 
patients with Ki-67 > 55%. However, it did not reach statistical significance when 
metformin was added, suggesting that probably a high Ki-67 level in the presence of 
metformin is not a predictor factor of pCR.
Conclusion: This is the first study conducted in a Latin American population 
showing that metformin with systemic therapy increases pCR regardless of the 
intrinsic molecular subtype or Ki-67 levels. These findings encourage prospective 
studies to evaluate the role of neoadjuvant metformin in this population. 
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2015, Costa Rica reported a BC incidence rate of 
2
42.25 per 100 000 women.  
BC is considered not a single disease, but a group 
of different entities with diverse pathological 
features, clinical implications, and outcomes.3 
Estrogen and progesterone receptors as well as 
HER2 expression (using immunohistochemistry), in 
conjunction with clinicopathological characteristics 
such as tumor grade, tumor size, and nodal 
involvement, are useful for establishing the 
4
management and prognosis of these patients.  Gene 
expression microarrays in BC have led to identifying 
of at least five molecular subtypes, labeled as 
luminal A, luminal B, HER2+, basal-like, and 
Introduction
According to the World Health Organization, 
breast cancer (BC) is one of the leading causes of 
morbidi ty  and morta l i ty  worldwide wi th 
1
approximately 14 million new cases in 2012.  In 
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5normal breast-like.  These BC subtypes have been 
associated with significant differences in overall 
6, 7
survival as well as response to systemic therapy.  
A recent meta-analysis showed that patients with 
BC who attain a pathological complete response 
(pCR) in the breast and axilla after neoadjuvant 
systemic treatment might have a better survival rate, 
mainly in aggressive tumors such as HER2 or triple-
8
negative (TN) subtypes.  Following this finding, the 
use of presurgical chemotherapy became very 
common, and biomarkers such as HER2, and 
hormone receptor (HR) status have been frequently 
used to indicate the implementation of this 
therapeutic approach. Furthermore, other markers 
have been explored to predict pCR, including Ki-67, 
which is a non-histone nuclear cortex protein 
expressed in the cell nucleus during the G1, S, G2, 
and M phases of the cell cycle. High Ki-67 levels 
have been associated with an increased chance of 
9-11
achieving pCR and therefore improved survival.
It has been proposed that hyperinsulinemia, 
insulin resistance as well as obesity influence breast 
cancer prognosis. Various mechanisms have been 
hypothesized, including increased circulating 
plasma levels of estrogen, insulin, insulin-like 
growth factor, and other hormonal factors that act to 
promote tumor growth and increase the risk of 
12-15 
metastatic disease.
Metformin is an oral biguanide used for treatment 
of type 2 diabetes that inhibits hepatic gluconeoge-
nesis and increases insulin sensitivity at peripheral 
16
level, thereby improving the glycemic control.  
Taking into account these pharmacological 
properties and the increasing evidence for the 
17
antitumor effect of metformin,  we decided to 
conduct a cross-sectional study to evaluate the 
impact of metformin on achieving pCR in breast 
cancer patients who received neoadjuvant 
chemotherapy in a Central American population. To 
our knowledge, this is the first study conducted in 
this region. 
Methods 
Study population
After receiving approval from the institutional 
ethics committee, we conducted a cross-sectional 
study from January 2007 to December 2015 in 
Mexico Hospital, San Jose, Costa Rica, to evaluate 
the pCR rate in patients with invasive breast cancer 
receiving neoadjuvant systemic therapy with or 
without metformin. We included all women with 
early-stage or locally advanced, biopsy-proven 
invasive breast cancer who received systemic 
treatment neoadjuvantly. The following exclusion 
criteria were used:  metformin use in a different 
proposed dosage (<  1 g/day), pregnancy, unknown 
HR or HER2 status, ECOG >  2, intolerance or 
hypersensitivity to metformin, not giving informed 
consent ,  having secondary or  concurrent 
malignancies except for controlled non-melanoma 
skin cancer or cervical carcinoma in situ. 
Treatment and pathology assessments 
Patients included were previously evaluated in 
the multidisciplinary tumor board. Overall, all 
patients received preoperative systemic therapy 
based  on  an thracyl ines  (ep i rub ic in)  and 
cyclophosphamide with or without 5-fluorouracil, 
followed by taxanes (paclitaxel). In case of HER2 
overexpression—determined using IHC or 
fluorescence in situ hybridization (FISH) 
trastuzumab was added to taxanes. Neoadjuvant 
hormonal  t reatment was al lowed without 
concomitant chemotherapy. After systemic therapy, 
patients underwent surgery (radical mastectomy, 
simple mastectomy, or conserving surgery) 
according to initial stage of the disease and response 
to systemic treatment. Also, the axilla was managed 
with sentinel node biopsy or axillary lymph node 
dissection. Adjuvant radiotherapy was given 
according to standard practice. In HR-positive 
tumors, adjuvant endocrine therapy was used, and 
HER2-positive tumors had to complete one year of 
adjuvant trastuzumab. When oral metformin was 
incorporated, the permitted dosage was 500 mg 
twice a day in conjunction with systemic therapy. 
Two experienced BC pathologists reviewed all 
the biopsies. The initial diagnosis was made using a 
breast or axillary node core needle biopsy. The report 
had to include a complete IHC (ER, PR, HER2, and 
Ki-67 percentage), tumor grade, and histologic 
subtype. In case of equivocal HER2 status by IHC, 
FISH would be performed. A pCR was defined as the 
absence of invasive carcinoma in breast or the 
axillary nodes in the surgical specimen (ypT0, 
ypN0). 
Statistics 
Demographic data are summarized and showed 
using descriptive statistics, and categorical variables 
are presented as percentages. Continuous variables are 
given as medians and ranges. The Fisher exact test was 
used to determine the association between metformin, 
immunophenotype, and pCR. A Multivariate logistic 
regression analysis was implemented to find potential 
predictors of pCR. We used the receiver operating 
characteristic (ROC) curve to establish the best cut-off 
point of Ki-67 for prediction of pCR. A P value less 
than 0.05 was considered statistically significant. Data 
were analyzed using SPSS (V. 20.0, Chicago, IL). 
Results 
We identified 81 women with invasive breast 
cancer who received neoadjuvant treatment. Fifty-
three women with early-stage or locally advanced 
breast cancer fulfilled the inclusion criteria and were 
enrolled. Of them, 14 patients received metformin 
(500 mg bid PO) during chemotherapy, and 39 were 
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treated with chemotherapy alone. (Figure 1)
Patient demographics and clinical characteristics 
of the groups are presented in Table 1. The mean age 
of the patients was 52.48 (range: 22–83) years. 
Overall, 56.6% of the patients did not have any 
comorbidities, 28.3% had hypertension, and 15.1% 
had type 2 diabetes mellitus. Two patients reported 
dyslipidemia, 1 patient had colon carcinoma more 
than five years before accrual, 1 patient had 
hypothyroidism, and 1 patient suffered from anxiety 
syndrome. 
Infiltrating ductal carcinoma was the most 
common histology (n = 49, 92.45%), followed by 
infiltrating lobular carcinoma (n = 2, 3.77%), 
medullar carcinoma (n = 1, 1.89%), and poorly 
differentiated carcinoma (n = 1, 1.89%). We found 
that 21 patients (40%) had luminal subtype, 20 
(38%) had TN tumors, 7 (13%) coexpressed estrogen 
receptor and HER2, and 10 cases (19%) were  
HER2+/HR-. Twenty-eight patients (53%) had 
grade3 tumors, 22 (43%) exhibited grade 2 invasive 
breast cancer, and only 3 patients (4%) had grade 1 
differentiation. In total, 35 women (67%) had 
lymphovascular invasion.
After neoadjuvant therapy (Table 2), 30 women 
(57%) had breast-conserving surgery and 23 (43%) 
had radical mastectomy. Eighteen patients (34%) 
achieved a pCR. We analyzed the pCR rate according 
to tumor subtype determined by IHC (Table 3). 
HER2-overexpressing tumors tended to predict pCR 
(OR: 3.88, P = 0.071), in contrast to luminal tumors, 
which did not achieve a pCR (OR 0.09; P = 0.01). 
When metformin was added to systemic therapy, a 
pCR rate of 64.3% was achieved, while the pCR rate 
in the systemic therapy-alone arm was 23.1% (OR: 
6.0, 95% CI: 1.60–22.53, P = 0.008). After 
adjustment for potential confounders (e.g., intrinsic 
breast cancer subtype assessed using immunohisto-  
Figure 1.  Consort Diagram
Table 1. Patient Demographics and Clinical Characteristics by Treatment Group
Age
<50 years 
≥50 years 
Clinical stagea
I 
II
III
Tumor IHC
HER2+
HER2-
RE+
RE-
50.3 (38–66)
 6 (42.8%)
 8 (57.2%)
0 (0.0%)
7 (50.0%)
7 (50.0%)
5 (35.7%)
9 (64.3%)
3 (21.4%)
11 (78.6%)
53.1 (22–83)
14 (35.9%)
25 (64.1%)
0 (0.0%)
17 (43.6%)
22 (56.4%)
12 (30.8%)
27 (69.2%)
19 (48.7%)
20 (51.3%)
Characteristics Systemic therapy + 
 metformin (N=14)
Systemic therapy alone 
(N=39)
a th
 TNM Stage according to AJCC Cancer Staging Manual 7  Ed.
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chemistry), metformin use was independently 
associated with a higher likelihood of pCR (OR: 
5.56, 95% CI: 1.27–24.3, P = 0.02) (Table 4). We also 
noted a trend for achieving a higher pCR rate in TN 
tumors when metformin was incorporated (OR: 10, 
95% CI: 1.03–67.1, P = 0.053). 
We decided to incorporate Ki-67 as a predictor 
marker for achieving pCR, with an 86% sensibility 
and 57% specificity when the cut-off was set at 55% 
(corresponding to the highest area under the ROC 
curve = 0.755). We found a higher chance of 
obtaining a pCR when Ki-67 percentage was greater 
than 55% (Table 5); however, when metformin was 
added to this model, we did not find a statistically 
significant increase in the rate of pCR in patients with 
Ki-67 > 55% (OR: 4.0, 95% CI: 0.36–44.1, P = 0.26).
We did not register any serious adverse events with 
metformin. Mild diarrhea was observed in 3 patients, 
which was controlled with short-term antidiarrheal 
medications. No other side effects were found. 
Discussion
Preoperative systemic therapy (neoadjuvant) is  
becoming popular nowadays for early-stage or 
locally advanced breast cancer. When this modality 
of treatment is given, the main purpose is to 
downstage the tumor for a less aggressive surgery 
with less postoperative complications and better 
18
cosmetic outcomes.  Neoadjuvant treatment also 
allows prompt tumor response evaluation, and the 
residual disease can be a prognostic factor of tumor 
recurrence and overall survival, mainly in high-risk 
histologies such as TN tumors or HER2+ invasive 
6, 8
breast carcinomas.  For this reason, there is a 
particular interest in exploring new therapies to 
increase the pCR rate. We decided to look at the 
effect of metformin plus standard therapy on the rate 
pCR. All the included patients were discussed in our 
institutional tumor board. As a result, there was a 
clear trend toward including more HER2+, TN, or 
HR-positive invasive breast cancer with high-risk 
features such as advanced disease or high histologic 
grade. This modality of treatment was also preferred 
in young patients, which explains the median age of 
52.48 (±13.41) years. Most of the patients in 
our study were healthy (56.6%). This fact is very 
Table 2. Neoadjuvant Systemic Treatment Used
Table 3. Association between IHC-determined tumor subtype and pathological complete response rate
Table 4. Multivariate Analysis of Potential Predictors of Pathological Complete Response
Table 5. Comparison of pCR by Ki-67 Percentage 
FEC* 75 followed by weekly paclitaxel.
FEC/EC 100 followed by weekly paclitaxel
Epirubicin followed by weekly paclitaxel + trastuzumab
Weekly paclitaxel + trastuzumab
Weekly paclitaxel alone
Dose-dense (epirubicin followed by paclitaxel)
Platinum/epirubicin/paclitaxel
Anastrozole
TOTAL
HR+/HER2-
HR+/HER2+
HR-/HER2+
Triple-negative
Total
Metformin
RE+
RE-/HER2+
Triple-negative
<55% (14)
>55% (21)
6
21
14
1
1
6
2
2
53
1 (6.7)
2 (28.6)
6 (60)
9 (42.9)
18
5.56 (1.27–24.3)
0.16 (0.01–2.39)
3.23 (0.837–29.16)
1.27 (0.17–9.31)
2 (14.3%)
12 (57.1%)
12 (85.7%)
9 (42.9%)
11.32%
39.62%
26.42%
1.89%
1.89%
11.32%
3.77%
3.77%
1%
14 (93.3)
5 (71.4)
4 (40)
12 (57.1)
35
0.09 (0.01–0.74)
P = 0.01
0.75 (0.13–4.31)
P = 0.555
3.88 (0.93–16.19)
P = 0.071
1.92 (0.60–6.10)
P = 0.37
-
0.02
0.18
0.28
0.17
8.0 (1.42–45.06), 0.013
N
Subtype 
Variable
Ki-67 (number)
With pCR, n (%) 
OR (95% CI)
With pCR, n (%) Without pCR, n (%)
Without pCR, n (%) OR (95% CI)
P
OR (95 CI %), P
percentage
*F= 5-Fluorouracil, E= Epirubicin, C= Cyclophosphamide 
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relevant because other retrospective studies using 
metformin in this setting had evaluated diabetic 
19
patients.  
Overall, the pCR rate (ypT0/is ypN0) obtained in 
our research was 34%, which is higher than that 
reported in other studies (ranging from 14 to 
20
19.8%).  Nevertheless, we have to emphasize that 
our study population was selected deliberately, 
including very responsive tumor subtypes. We found 
that the pCR rate was significantly higher when 
metformin was added to standard systemic therapy, 
even after adjustment for the tumor subtype, 
meaning that adding metformin to systemic therapy 
increased the likelihood of achieving pCR 5.56 
times. 
Metformin has shown anticancer properties, 
including activation of the AMP activated protein 
21
kinase (AMPK) pathway,  antioxidant activity, 
22
induction of apoptosis, and many others.  Patients 
with type 2 diabetes are hyperinsulinemic, and there 
is evidence that this condition contributes to 
tumorigenesis. In this scenario, metformin reverses, 
at least partially, hyperinsulinemia and exhibits 
antiproliferative properties, which might increase 
the effect of chemotherapy in a synergy. Preclinical 
research has demonstrated that metformin can 
sensitize tumor cells to chemotherapy through 
23
inhibition of the expression of PI3K/AKT proteins  
and, consequently, controlling the activity of the 
mammalian target of rapamycin (mTOR). The 
combination of metformin with chemotherapy 
appears to inhibit mTOR activity, inducing cell cycle 
24
arrest.  Our study, although limited by its cross-
sectional design and sample size, provides clinical 
evidence that metformin in conjunction with 
chemotherapy increases the pCR rate in the context 
of non-diabetic Latin American patients, which is 
relevant to planning prospective studies. 
Ki-67 is a non-histone nuclear cortex protein 
expressed in all cell cycle phases except in the 
quiescent phase G0, reaching the peak level during 
mitosis. Ki-67 can serve as an indicator of tumor 
10, 25, 26
proliferative activity.  Higher level of Ki-67 has 
27, 
been hypothesized to be a predictor marker of pCR.
28
 A recent meta analysis involving 53 studies (10 848 
patients) showed that tumors with high Ki-67 score 
had a better chance to respond to neoadjuvant 
29
treatment, although there was no clear cut-off.  In 
our study, there was a higher chance of obtaining a 
pCR when Ki-67 index was greater than 55% using 
ROC curve; however, when metformin was added, 
we were unable to find a specific Ki-67 cut-off. This 
might mean that, regardless of Ki-67 levels, the most 
important factor to obtain the pCR was metformin. 
This finding must be confirmed by future studies 
since this has not been evaluated in this specific 
approach, as far as we know, either in retrospective 
or prospective studies. 
In conclusion, this is the first cross-sectional 
study conducted in a Latin American population 
showing that the use of metformin in combination 
with systemic therapy can increase the pCR rate in 
locally advanced or early breast cancer, irrespective 
of the histologic subtype, grade, or Ki-67 levels. 
These findings can encourage prospective studies 
using metformin in the neoadjuvant setting in our 
population. 
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